Please Wait
Applying Filters...
menu
    • menu
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    LOXO 292

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lilly opens phase 3 trial in RET-mutant medullary thyroid cancer
    Lilly opens phase 3 trial in RET-mutant medullary thyroid cancer

    31 Dec 2019

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=120270&sid=2

    PHARMABIZ
    31 Dec 2019
    Share Share
    Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'
    Inside drugmakers' strategy to boost cancer medicines with 'Lazarus effect'

    06 Sep 2019

    // REUTERS

    https://in.reuters.com/article/us-bayer-cancer-insight/inside-drugmakers-strategy-to-boost-cancer-medicines-with-lazarus-effect-idINKCN1VR0EA

    REUTERS
    06 Sep 2019
    Share Share
    Shrinking 60% of lung cancers, Blueprint's RET drug poised for 2020 filing
    Shrinking 60% of lung cancers, Blueprint's RET drug poised for 2020 filing

    04 Jun 2019

    // Amirah Al Idrus FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/asco-shrinking-60-lung-cancers-blueprint-s-ret-drug-poised-for-2020-filing

    Amirah Al Idrus FIERCE BIOTECH
    04 Jun 2019
    Share Share
    As Lilly deal closes, Bayer secures full rights to Loxo's Vitrakvi
    As Lilly deal closes, Bayer secures full rights to Loxo's Vitrakvi

    16 Feb 2019

    // Ned Pagliarulo BIOPHARMA DIVE

    https://www.biopharmadive.com/news/as-lilly-deal-closes-bayer-secures-full-rights-to-loxos-vitrakvi/548584/

    Ned Pagliarulo BIOPHARMA DIVE
    16 Feb 2019
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.